We first characterized the expression of PRDM3 and its relevance to pancreatic cancer prognosis by analyzing a cohort of 94 patients who were diagnosed with PDAC and received surgical resection without preoperative chemotherapy. This evidence concerns the gene MECOM and pancreatic neoplasm.